Fresenius Medical Care AG & Co. KGAA (ETR:FME) received a €95.60 ($113.81) target price from J P Morgan Chase & Co in a research note issued to investors on Tuesday. The firm currently has a “buy” rating on the stock. J P Morgan Chase & Co’s target price would suggest a potential upside of 11.96% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Deutsche Bank set a €84.00 ($100.00) price target on Fresenius Medical Care AG & Co. KGAA and gave the stock a “neutral” rating in a report on Tuesday, August 8th. Citigroup set a €92.00 ($109.52) price target on Fresenius Medical Care AG & Co. KGAA and gave the stock a “buy” rating in a report on Tuesday, August 8th. Goldman Sachs Group set a €97.00 ($115.48) price target on Fresenius Medical Care AG & Co. KGAA and gave the stock a “buy” rating in a report on Tuesday, August 8th. Commerzbank set a €88.00 ($104.76) price target on Fresenius Medical Care AG & Co. KGAA and gave the stock a “neutral” rating in a report on Monday, August 7th. Finally, Independent Research set a €88.00 ($104.76) target price on Fresenius Medical Care AG & Co. KGAA and gave the company a “neutral” rating in a report on Tuesday, August 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of €89.06 ($106.03).

Fresenius Medical Care AG & Co. KGAA (FME) opened at €85.39 ($101.65) on Tuesday. Fresenius Medical Care AG & Co. KGAA has a fifty-two week low of €71.49 ($85.11) and a fifty-two week high of €89.22 ($106.21).

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/fresenius-medical-care-ag-95-60-price-target-at-j-p-morgan-chase-co.html.

About Fresenius Medical Care AG & Co. KGAA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. KGAA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGAA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGAA and related companies with MarketBeat.com's FREE daily email newsletter.